文献速递淋巴瘤

苯达莫司汀治疗惰性非霍奇金淋巴瘤的安全性:英国真实世界经验

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.
PubMed 文献 · Blood Adv · 2024-01-01

这项多中心观察性研究纳入9家英国国家医疗服务体系医院的323例接受苯达莫司汀(联合或不联合利妥昔单抗)治疗的惰性B细胞非霍奇金淋巴瘤患者,21.7%发生治疗相关严重不良事件,感染最常见(12%),2.8%死于苯达莫司汀相关感染、骨髓增生异常综合征和心脏病。作者认为需要延长抗微生物预防和感染监测,尤其是维持治疗患者。

要点

  • 21.7%患者发生治疗相关严重不良事件,感染占12%。
  • 2.8%患者死于苯达莫司汀相关感染、骨髓增生异常综合征和心脏病。
  • 作者建议延长抗微生物预防和感染监测,尤其对维持治疗患者。

核心结论

  • 在真实世界分析中,苯达莫司汀相关死亡和治疗中断与较年轻、体能较好的试验人群相似。
  • 体能状态差、套细胞组织学和利妥昔单抗维持治疗是潜在危险因素。
  • 感染包括晚发事件是最常见的治疗相关严重不良事件和死亡原因,作者认为需要延长抗微生物预防和感染监测,尤其是维持治疗患者。

研究设计与样本

  • 多中心观察性研究,纳入9家英国国家医疗服务体系医院接受至少1剂苯达莫司汀(联合或不联合利妥昔单抗)治疗的惰性非霍奇金淋巴瘤患者,共323例。

主要发现

  • 96%患者接受苯达莫司汀联合利妥昔单抗,46%接受利妥昔单抗维持治疗。
  • 21.7%患者发生治疗相关严重不良事件,其中感染占12%。
  • 严重不良事件绝对风险在诱导期最高(63%),维持期20%,随访期17%;相对风险在维持期最高(54%),诱导期34%,随访期28%。
  • 13%患者因毒性永久终止治疗,2.8%死于苯达莫司汀相关感染(n=5)、骨髓增生异常综合征(n=3)和心脏病(n=1)。
  • 套细胞淋巴瘤、诱导前体能状态差、维持前体能状态差、诱导前总球蛋白异常以及接受生长因子治疗的患者中,每例患者报告的严重不良事件更多。

临床怎么用

  • 作者认为需要延长抗微生物预防和感染监测,尤其是维持治疗患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bendamustine is among the most effective chemotherapeutics for indolent B-cell non-Hodgkin lymphomas (iNHL), but trial reports of significant toxicity, including opportunistic infections and excess deaths, led to prescriber warnings. We conducted a multicenter observational study evaluating bendamustine toxicity in real-world practice. Patients receiving at least 1 dose of bendamustine with/without rituximab (R) for iNHL were included. Demographics, lymphoma and treatment details, and grade 3 to 5 adverse events (AEs) were analyzed and correlated. In total, 323 patients were enrolled from 9 National Health Service hospitals. Most patients (96%) received bendamustine-R, and 46%, R maintenance. Overall, 21.7% experienced serious AEs (SAE) related to treatment, including infections in 12%, with absolute risk highest during induction (63%), maintenance (20%), and follow-up (17%) and the relative risk highest during maintenance (54%), induction (34%), and follow-up (28%). Toxicity led to permanent treatment discontinuation for 13% of patients, and 2.8% died of bendamustine-related infections (n = 5), myelodysplastic syndrome (n = 3), and cardiac disease (n = 1). More SAEs per patient were reported in patients with mantle cell lymphoma, poor preinduction performance status (PS), poor premaintenance PS, and abnormal preinduction total globulins and in those receiving growth factors. Use of antimicrobial prophylaxis was variable, and 3 of 10 opportunistic infections occurred despite prophylaxis. In this real-world analysis, bendamustine-related deaths and treatment discontinuation were similar to those of trial populations of younger, fitter patients. Poor PS, mantle cell histology, and maintenance R were potential risk factors. Infections, including late onset events, were the most common treatment-related SAE and cause of death, warranting extended antimicrobial prophylaxis and infectious surveillance, especially for maintenance-treated patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Shotton R, Broadbent R, Alchawaf A, et al. Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience. Blood Adv. 2024. PMID: 37967358. doi:10.1182/bloodadvances.2023011305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。